Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
about
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsBovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.Adenoviral vector immunity: its implications and circumvention strategies.The influence of innate and pre-existing immunity on adenovirus therapyCanine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway.Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaquesImmunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityInduction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.Current strategies and future directions for eluding adenoviral vector immunityProtective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.Genetic medicine strategies to protect against bioterrorism.Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunityA novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expressionComparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and DDevelopment of nonhuman adenoviruses as vaccine vectors.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivectorConstruction, rescue, and characterization of vectors derived from ovine atadenovirus.Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.An update on canine adenovirus type 2 and its vectors.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted.Biology of ovine adenovirus infection of nonpermissive cells.Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3.Development and assessment of human adenovirus type 11 as a gene transfer vector.Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus.
P2860
Q26776553-17DA1DC6-DC84-4E0E-AEF0-21E2175BC7D8Q26782083-BCCC63B9-FE0A-40B1-9C30-0B39E6EC0C7BQ26995655-64A3741E-8AD8-4453-B956-7263CD4ECD4AQ30229074-F949A870-9DF1-4EA1-A06F-207400553A54Q33565630-07924F1C-7C38-42F6-BE62-0A2BA17ED803Q33655401-513582E4-092A-44E3-BF8B-3FA4BA36EE3FQ33787309-616F25B4-5411-4AAA-B0A1-D614BE476F97Q33877458-7EC6F8AF-DEAE-4363-8E61-816A3D0EDDECQ33908767-7589AF2D-3AAE-44AF-8207-8C4FC3B3B979Q34033557-FCFC84FC-1DE4-4847-AE19-B489248AFEC2Q34332885-7CA52AAC-E148-47FD-B38E-4B1D1D872A7BQ34585554-565CAE46-9C5B-461C-BFAA-563FAEF4AC30Q34701517-FF06B9F4-0543-4780-9DDF-02F46A1FF69EQ34767181-9ED11022-EB83-4A19-900A-6786016D00B5Q35155049-ABD6D308-BA11-49E1-BA4B-CF15A23DB70EQ35641856-188D9016-D72E-4664-8C76-9649373D3FAEQ35857420-8B5F19FF-9926-49A3-8472-D5B40151AE67Q36317264-40C264D9-EA03-462B-9C4A-24D68F629793Q36498186-D9719243-FACA-4CEE-829C-02B809F6816BQ36751598-6089DE52-EE40-46B8-B792-6715556E4803Q36890695-9EF64A83-69E2-48BB-8EF3-042A8F5CC112Q37309252-EF98A128-089C-462A-84D4-3F30CA544228Q37596543-BD729CAE-5A65-434A-8B16-5892AC82376DQ37945220-836B40E5-E84E-4B6E-A25D-CDFD6ECA31FBQ38284700-A493D816-7C33-4554-98D2-F56ECC9F43EAQ39683618-61B260C7-0099-4BFA-BE69-A08474F4AD25Q39685343-5A3D38EA-4472-46B8-86F0-D7D73D58B034Q40424773-6A2927D4-E694-4DC5-8B86-7CE9B50579E8Q40441928-DA57296F-13A4-4004-8A2C-6BB1A9C7BD0DQ40624940-0D599D96-6786-4340-B405-E1DF5DC67B88Q42376165-3F915F20-37F6-4A47-9A64-DD4139E20A30
P2860
Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@ast
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@en
type
label
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@ast
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@en
prefLabel
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@ast
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@en
P2093
P2860
P1433
P1476
Ovine adenovirus vectors overc ...... nst human adenoviruses in vivo
@en
P2093
P2860
P304
P577
1999-08-01T00:00:00Z